Subjects with coronary artery disease and reduced ejection fraction have longer (GT)n repeats in the heme-oxygenase 1 gene promoter

Heme oxygenase (HO)-1 is a rate-limiting enzyme for degrading heme into carbon monoxide. Longer (GT) n repeat of the HO-1 gene (HMOX1) promoter has a lower transcription rate. Subjects with longer GT repeats in the HMOX1 promoter are more likely to have coronary artery disease (CAD) and cardiovascul...

Full description

Saved in:
Bibliographic Details
Published inHeart and vessels Vol. 36; no. 5; pp. 615 - 620
Main Authors Liang, Kae-Woei, Lee, Wen-Jane, Lee, Wen-Lieng, Wu, Jen-Pey, Lee, I-Te, Wang, Jun-Sing, Sheu, Wayne H.-H.
Format Journal Article
LanguageEnglish
Published Tokyo Springer Japan 01.05.2021
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Heme oxygenase (HO)-1 is a rate-limiting enzyme for degrading heme into carbon monoxide. Longer (GT) n repeat of the HO-1 gene (HMOX1) promoter has a lower transcription rate. Subjects with longer GT repeats in the HMOX1 promoter are more likely to have coronary artery disease (CAD) and cardiovascular events. We retrospectively enrolled CAD subjects with an abnormal ejection fraction (EF) < 50% from our catheterization data ( N  = 670). Polymerase chain reactions were performed for amplifying the HMOX1 promoter GT repeating segment to determine the number of repeats. Two subgroups, reduced EF < 40% ( N  = 256), and mid-range EF 40–49% ( N  = 414), were compared. The distribution of genotypes of SS, SL and LL were significantly different in reduced EF (29%, 48%, 23%) vs. mid-range EF CAD (64%, 30%, 5%) (S allele: ≤ 30 repeats, L allele: > 30 repeats) ( p  < 0.001). The patients with reduced EF had a significantly longer average (GT) n (median 27.5 vs. 26.5, p  = 0.004) than those with the mid-range EF. In multivariate analysis, the carrier of L allele (odds ratio 4.437, p  < 0.001) was a significant predictor for the diagnosis of reduced vs. mid-range EF CAD. In conclusion, CAD patients with reduced EF had longer HMOX1 promoter (GT) n repeats than those with mid-range EF.
AbstractList Heme oxygenase (HO)-1 is a rate-limiting enzyme for degrading heme into carbon monoxide. Longer (GT) repeat of the HO-1 gene (HMOX1) promoter has a lower transcription rate. Subjects with longer GT repeats in the HMOX1 promoter are more likely to have coronary artery disease (CAD) and cardiovascular events. We retrospectively enrolled CAD subjects with an abnormal ejection fraction (EF) < 50% from our catheterization data (N = 670). Polymerase chain reactions were performed for amplifying the HMOX1 promoter GT repeating segment to determine the number of repeats. Two subgroups, reduced EF < 40% (N = 256), and mid-range EF 40-49% (N = 414), were compared. The distribution of genotypes of SS, SL and LL were significantly different in reduced EF (29%, 48%, 23%) vs. mid-range EF CAD (64%, 30%, 5%) (S allele: ≤ 30 repeats, L allele: > 30 repeats) (p < 0.001). The patients with reduced EF had a significantly longer average (GT) (median 27.5 vs. 26.5, p = 0.004) than those with the mid-range EF. In multivariate analysis, the carrier of L allele (odds ratio 4.437, p < 0.001) was a significant predictor for the diagnosis of reduced vs. mid-range EF CAD. In conclusion, CAD patients with reduced EF had longer HMOX1 promoter (GT) repeats than those with mid-range EF.
Heme oxygenase (HO)-1 is a rate-limiting enzyme for degrading heme into carbon monoxide. Longer (GT)n repeat of the HO-1 gene (HMOX1) promoter has a lower transcription rate. Subjects with longer GT repeats in the HMOX1 promoter are more likely to have coronary artery disease (CAD) and cardiovascular events. We retrospectively enrolled CAD subjects with an abnormal ejection fraction (EF) < 50% from our catheterization data (N = 670). Polymerase chain reactions were performed for amplifying the HMOX1 promoter GT repeating segment to determine the number of repeats. Two subgroups, reduced EF < 40% (N = 256), and mid-range EF 40–49% (N = 414), were compared. The distribution of genotypes of SS, SL and LL were significantly different in reduced EF (29%, 48%, 23%) vs. mid-range EF CAD (64%, 30%, 5%) (S allele: ≤ 30 repeats, L allele: > 30 repeats) (p < 0.001). The patients with reduced EF had a significantly longer average (GT)n (median 27.5 vs. 26.5, p = 0.004) than those with the mid-range EF. In multivariate analysis, the carrier of L allele (odds ratio 4.437, p < 0.001) was a significant predictor for the diagnosis of reduced vs. mid-range EF CAD. In conclusion, CAD patients with reduced EF had longer HMOX1 promoter (GT)n repeats than those with mid-range EF.
Heme oxygenase (HO)-1 is a rate-limiting enzyme for degrading heme into carbon monoxide. Longer (GT) n repeat of the HO-1 gene (HMOX1) promoter has a lower transcription rate. Subjects with longer GT repeats in the HMOX1 promoter are more likely to have coronary artery disease (CAD) and cardiovascular events. We retrospectively enrolled CAD subjects with an abnormal ejection fraction (EF) < 50% from our catheterization data ( N  = 670). Polymerase chain reactions were performed for amplifying the HMOX1 promoter GT repeating segment to determine the number of repeats. Two subgroups, reduced EF < 40% ( N  = 256), and mid-range EF 40–49% ( N  = 414), were compared. The distribution of genotypes of SS, SL and LL were significantly different in reduced EF (29%, 48%, 23%) vs. mid-range EF CAD (64%, 30%, 5%) (S allele: ≤ 30 repeats, L allele: > 30 repeats) ( p  < 0.001). The patients with reduced EF had a significantly longer average (GT) n (median 27.5 vs. 26.5, p  = 0.004) than those with the mid-range EF. In multivariate analysis, the carrier of L allele (odds ratio 4.437, p  < 0.001) was a significant predictor for the diagnosis of reduced vs. mid-range EF CAD. In conclusion, CAD patients with reduced EF had longer HMOX1 promoter (GT) n repeats than those with mid-range EF.
Heme oxygenase (HO)-1 is a rate-limiting enzyme for degrading heme into carbon monoxide. Longer (GT)n repeat of the HO-1 gene (HMOX1) promoter has a lower transcription rate. Subjects with longer GT repeats in the HMOX1 promoter are more likely to have coronary artery disease (CAD) and cardiovascular events. We retrospectively enrolled CAD subjects with an abnormal ejection fraction (EF) < 50% from our catheterization data (N = 670). Polymerase chain reactions were performed for amplifying the HMOX1 promoter GT repeating segment to determine the number of repeats. Two subgroups, reduced EF < 40% (N = 256), and mid-range EF 40-49% (N = 414), were compared. The distribution of genotypes of SS, SL and LL were significantly different in reduced EF (29%, 48%, 23%) vs. mid-range EF CAD (64%, 30%, 5%) (S allele: ≤ 30 repeats, L allele: > 30 repeats) (p < 0.001). The patients with reduced EF had a significantly longer average (GT)n (median 27.5 vs. 26.5, p = 0.004) than those with the mid-range EF. In multivariate analysis, the carrier of L allele (odds ratio 4.437, p < 0.001) was a significant predictor for the diagnosis of reduced vs. mid-range EF CAD. In conclusion, CAD patients with reduced EF had longer HMOX1 promoter (GT)n repeats than those with mid-range EF.Heme oxygenase (HO)-1 is a rate-limiting enzyme for degrading heme into carbon monoxide. Longer (GT)n repeat of the HO-1 gene (HMOX1) promoter has a lower transcription rate. Subjects with longer GT repeats in the HMOX1 promoter are more likely to have coronary artery disease (CAD) and cardiovascular events. We retrospectively enrolled CAD subjects with an abnormal ejection fraction (EF) < 50% from our catheterization data (N = 670). Polymerase chain reactions were performed for amplifying the HMOX1 promoter GT repeating segment to determine the number of repeats. Two subgroups, reduced EF < 40% (N = 256), and mid-range EF 40-49% (N = 414), were compared. The distribution of genotypes of SS, SL and LL were significantly different in reduced EF (29%, 48%, 23%) vs. mid-range EF CAD (64%, 30%, 5%) (S allele: ≤ 30 repeats, L allele: > 30 repeats) (p < 0.001). The patients with reduced EF had a significantly longer average (GT)n (median 27.5 vs. 26.5, p = 0.004) than those with the mid-range EF. In multivariate analysis, the carrier of L allele (odds ratio 4.437, p < 0.001) was a significant predictor for the diagnosis of reduced vs. mid-range EF CAD. In conclusion, CAD patients with reduced EF had longer HMOX1 promoter (GT)n repeats than those with mid-range EF.
Author Wang, Jun-Sing
Lee, I-Te
Liang, Kae-Woei
Wu, Jen-Pey
Sheu, Wayne H.-H.
Lee, Wen-Lieng
Lee, Wen-Jane
Author_xml – sequence: 1
  givenname: Kae-Woei
  orcidid: 0000-0003-0991-9614
  surname: Liang
  fullname: Liang, Kae-Woei
  email: ekwliang@gmail.com
  organization: Cardiovascular Center, Taichung Veterans General Hospital, Department of Medicine, School of Medicine, National Yang Ming University
– sequence: 2
  givenname: Wen-Jane
  surname: Lee
  fullname: Lee, Wen-Jane
  organization: Department of Medical Research, Taichung Veterans General Hospital, Department of Social Work, Tunghai University
– sequence: 3
  givenname: Wen-Lieng
  surname: Lee
  fullname: Lee, Wen-Lieng
  organization: Cardiovascular Center, Taichung Veterans General Hospital, Department of Medicine, School of Medicine, National Yang Ming University
– sequence: 4
  givenname: Jen-Pey
  surname: Wu
  fullname: Wu, Jen-Pey
  organization: Department of Medical Research, Taichung Veterans General Hospital
– sequence: 5
  givenname: I-Te
  surname: Lee
  fullname: Lee, I-Te
  organization: Department of Medicine, School of Medicine, National Yang Ming University, Division of Endocrinology and Metabolism, Department of Medicine, Taichung Veterans General Hospital
– sequence: 6
  givenname: Jun-Sing
  surname: Wang
  fullname: Wang, Jun-Sing
  organization: Department of Medicine, School of Medicine, National Yang Ming University, Division of Endocrinology and Metabolism, Department of Medicine, Taichung Veterans General Hospital
– sequence: 7
  givenname: Wayne H.-H.
  surname: Sheu
  fullname: Sheu, Wayne H.-H.
  organization: Department of Medicine, School of Medicine, National Yang Ming University, Division of Endocrinology and Metabolism, Department of Medicine, Taichung Veterans General Hospital, Institute of Biomedical Sciences, National Chung Hsing University, School of Medicine, National Defense Medical Center
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33388910$$D View this record in MEDLINE/PubMed
BookMark eNp9kcFu1DAQhi1URLeFF-CALHEph4DtSTbOEVWlIFXiQDlbjj3pZpXYi50Ueu6LMyEFpB56sGckf__MeP4TdhRiQMZeS_FeClF_yEKAFoVQdGQNUNTP2EZuZVWoqoYjthGNFIUGVR-zk5z3Qsiqkc0LdgwAWtPjht1_m9s9uinzn_204y6mGGy64zZNSMH3GW1GboPnCf3s0HNc-D4G3iW7Jjt7i3yI4QYTP7u8fheIPaClon3g0w75Dkcs4q-7GwxLNckpQX5IcYzU5iV73tkh46uHeMq-f7q4Pv9cXH29_HL-8apwIMu6gNJr17qykq3flrb1DpRuhewsbD1Yj0J1oCz4ji7V1VCh3pb0Yee07loLp-xsrUuNf8yYJzP22eEw2IBxzkaVdSUaWmlJ6NtH6D7OKdB0RlVSqEarShD15oGa2xG9OaR-pOWZv-slQK2ASzHnhN0_RAqzeGhWDw15aP54aGoS6Uci1092WfSUbD88LYVVmqnPYsf_sZ9Q_QZt-bDI
CitedBy_id crossref_primary_10_1080_1354750X_2021_1992650
crossref_primary_10_3390_antiox11030555
crossref_primary_10_1016_j_bcp_2021_114661
crossref_primary_10_3892_mmr_2021_12545
crossref_primary_10_3390_cells10030515
crossref_primary_10_1038_s41598_023_44065_y
crossref_primary_10_1536_ihj_23_207
crossref_primary_10_1161_JAHA_123_033981
Cites_doi 10.1161/CIR.0000000000000509
10.1161/ATVBAHA.114.304729
10.1093/eurheartj/ehv544
10.1007/s00246-015-1146-0
10.1016/S1726-4901(09)70035-8
10.1161/hh1401.093314
10.1161/ATVBAHA.110.207316
10.1093/aje/kwu024
10.1089/ars.2010.3726
10.1161/01.ATV.0000033515.96747.6F
10.1161/CIRCULATIONAHA.107.698316
10.1161/CIRCULATIONAHA.109.905471
10.1177/152660280100800501
10.18632/oncotarget.13118
10.1016/j.ejphar.2014.03.026
10.1007/s00439-002-0769-4
10.2337/diabetes.54.3.778
10.1016/j.cjca.2015.06.006
10.1016/j.ehj.2003.10.009
10.1016/j.jacc.2008.06.019
10.1093/aje/kwq162
10.1093/eurheartj/ehw128
10.1172/JCI6163
10.1016/j.jcma.2013.03.005
10.1161/ATVBAHA.107.160085
10.1186/1423-0127-17-12
ContentType Journal Article
Copyright Springer Japan KK, part of Springer Nature 2021
Springer Japan KK, part of Springer Nature 2021.
Copyright_xml – notice: Springer Japan KK, part of Springer Nature 2021
– notice: Springer Japan KK, part of Springer Nature 2021.
DBID AAYXX
CITATION
NPM
7QO
8FD
FR3
K9.
P64
7X8
DOI 10.1007/s00380-020-01733-7
DatabaseName CrossRef
PubMed
Biotechnology Research Abstracts
Technology Research Database
Engineering Research Database
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
ProQuest Health & Medical Complete (Alumni)
Engineering Research Database
Biotechnology Research Abstracts
Technology Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList PubMed
ProQuest Health & Medical Complete (Alumni)

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1615-2573
EndPage 620
ExternalDocumentID 33388910
10_1007_s00380_020_01733_7
Genre Journal Article
GrantInformation_xml – fundername: Taichung Veterans General Hospital
  grantid: TCVGH-1083105C, 1087314C, 1073108C, 1063102B, 1067328D, 1067314C
  funderid: http://dx.doi.org/10.13039/501100010101
– fundername: Taichung Veterans General Hospital
  grantid: TCVGH-1083105C, 1087314C, 1073108C, 1063102B, 1067328D, 1067314C
GroupedDBID ---
-53
-5E
-5G
-BR
-EM
-Y2
-~C
.86
.GJ
.VR
06C
06D
0R~
0VY
1N0
1SB
203
28-
29I
29~
2J2
2JN
2JY
2KG
2LR
2P1
2VQ
2~H
30V
36B
3O-
3V.
4.4
406
408
409
40D
40E
53G
5GY
5QI
5RE
5VS
67Z
6NX
7X7
88E
8AO
8FI
8FJ
8G5
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABKTR
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFS
ACHSB
ACHXU
ACIWK
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACUDM
ACZOJ
ADBBV
ADHHG
ADHIR
ADIMF
ADINQ
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFEXP
AFKRA
AFLOW
AFQWF
AFRAH
AFWTZ
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
AZQEC
B-.
BA0
BBWZM
BDATZ
BENPR
BGNMA
BPHCQ
BSONS
BVXVI
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
DU5
DWQXO
EBD
EBLON
EBS
EIOEI
EJD
EMB
EMOBN
EN4
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNUQQ
GNWQR
GQ6
GQ7
GQ8
GRRUI
GUQSH
GXS
H13
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IHE
IJ-
IKXTQ
IMOTQ
IWAJR
IXC
IXD
IXE
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KOW
KPH
LAS
LLZTM
M1P
M2O
M4Y
MA-
N2Q
N9A
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
P19
P9S
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R4E
R89
R9I
RHV
RIG
RNI
ROL
RPX
RRX
RSV
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SCLPG
SDE
SDH
SDM
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK8
YLTOR
Z45
Z7U
Z82
Z87
Z8O
Z8V
Z91
ZGI
ZMTXR
ZOVNA
ZXP
~A9
~EX
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ACSTC
ADHKG
AEZWR
AFDZB
AFHIU
AFOHR
AGQPQ
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
NPM
7QO
8FD
ABRTQ
FR3
K9.
P64
7X8
ID FETCH-LOGICAL-c3147-34d8cbc451bd64abdc328b01fa36d3ade02f32a3df2a32f735e864919cc88fba3
IEDL.DBID U2A
ISSN 0910-8327
1615-2573
IngestDate Fri Jul 11 01:51:24 EDT 2025
Sat Aug 16 15:21:47 EDT 2025
Thu Apr 03 07:07:50 EDT 2025
Tue Jul 01 00:51:10 EDT 2025
Thu Apr 24 22:58:57 EDT 2025
Fri Feb 21 02:48:37 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords Coronary artery disease (CAD)
Heart failure with reduced ejection fraction
Promoter polymorphism
Heme oxygenase (HO)-1
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3147-34d8cbc451bd64abdc328b01fa36d3ade02f32a3df2a32f735e864919cc88fba3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-0991-9614
PMID 33388910
PQID 2510298250
PQPubID 36867
PageCount 6
ParticipantIDs proquest_miscellaneous_2475093804
proquest_journals_2510298250
pubmed_primary_33388910
crossref_primary_10_1007_s00380_020_01733_7
crossref_citationtrail_10_1007_s00380_020_01733_7
springer_journals_10_1007_s00380_020_01733_7
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20210500
PublicationDateYYYYMMDD 2021-05-01
PublicationDate_xml – month: 5
  year: 2021
  text: 20210500
PublicationDecade 2020
PublicationPlace Tokyo
PublicationPlace_xml – name: Tokyo
– name: Japan
PublicationTitle Heart and vessels
PublicationTitleAbbrev Heart Vessels
PublicationTitleAlternate Heart Vessels
PublicationYear 2021
Publisher Springer Japan
Springer Nature B.V
Publisher_xml – name: Springer Japan
– name: Springer Nature B.V
References Dulak, Deshane, Jozkowicz, Agarwal (CR5) 2008; 117
CR19
Lin, Yang (CR6) 2009; 72
Liu, Wei, Peng, Layne, Yet (CR27) 2005; 54
Idriss, Blann, Lip (CR3) 2008; 52
Wang, Hamid, Keith, Zhou, Partridge, Xiang, Kingery, Lewis, Li, Rokosh, Ford, Spinale, Riggs, Srivastava, Bhatnagar, Bolli, Prabhu (CR9) 2010; 121
Pechlaner, Willeit, Summerer, Santer, Egger, Kronenberg, Demetz, Weiss, Tsimikas, Witztum, Willeit, Iglseder, Paulweber, Kedenko, Haun, Meisinger, Gieger, Muller-Nurasyid, Peters, Willeit, Kiechl (CR22) 2015; 35
Ndisang, Chibbar, Lane (CR11) 2014; 734
Taha, Skrzypek, Guevara, Nigisch, Mustafa, Grochot-Przeczek, Ferdek, Was, Kotlinowski, Kozakowska, Balcerczyk, Muchova, Vitek, Weigel, Dulak, Jozkowicz (CR14) 2010; 30
Bao, Song, Li, Rong, Yang, Wang, Xu, Fu, Zhao, Liu (CR20) 2010; 172
Sianos, Morel, Kappetein, Morice, Colombo, Dawkins, van den Brand, Van Dyck, Russell, Mohr, Serruys (CR25) 2005; 1
Sayed, Idriss, Blann, Sayyed, Raafat, Fouad, Tawfeek (CR24) 2015; 36
Yet, Perrella, Layne, Hsieh, Maemura, Kobzik, Wiesel, Christou, Kourembanas, Lee (CR26) 1999; 103
Ponikowski, Voors, Anker, Bueno, Cleland, Coats, Falk, Gonzalez-Juanatey, Harjola, Jankowska, Jessup, Linde, Nihoyannopoulos, Parissis, Pieske, Riley, Rosano, Ruilope, Ruschitzka, Rutten, van der Meer (CR1) 2016; 37
Furchgott, Jothianandan (CR4) 1991; 28
Wenzel, Rossmann, Muller, Kossmann, Oelze, Schulz, Arnold, Simsek, Lagrange, Klemz, Schonfelder, Brandt, Karbach, Knorr, Finger, Neukirch, Hauser, Beutel, Kroller-Schon, Schulz, Schnabel, Lackner, Wild, Zeller, Daiber, Blankenberg, Munzel (CR28) 2015; 36
Liang, Sheu, Lee, Lee, Lin, Ting, Lee (CR23) 2013; 76
Kaneda, Ohno, Taguchi, Togo, Hashimoto, Ogasawara, Aizawa, Ishizaka, Nagai (CR16) 2002; 22
Wu, Ho, Lin, Yet (CR7) 2011; 1
Yet, Tian, Layne, Wang, Maemura, Solovyeva, Ith, Melo, Zhang, Ingwall, Dzau, Lee, Perrella (CR10) 2001; 89
Daenen, Martens, Bammens (CR18) 2016; 32
Chen, Chau, Lin, Chen, Yo, Chen, Lin (CR21) 2004; 25
Wu, Ho, Yet (CR8) 2011; 15
Exner, Schillinger, Minar, Mlekusch, Schlerka, Haumer, Mannhalter, Wagner (CR13) 2001; 8
Chen, Lin, Lin, Tsai, Kuo, Chen, Charng, Wu, Chen, Ding, Pan, Jou, Chau (CR12) 2002; 111
Qiao, Sai, Gai, Huang, Chen, Tu, Ding (CR15) 2014; 179
Lin, Liu, Peyton, Wang, Yang, Lin, Durante (CR29) 2008; 28
Zhang, Zheng, Gao, Zhang, Liu, Yang, Li, Ma, Xie (CR17) 2016; 7
Yancy, Jessup, Bozkurt, Butler, Casey, Colvin, Drazner, Filippatos, Fonarow, Givertz, Hollenberg, Lindenfeld, Masoudi, McBride, Peterson, Stevenson, Westlake (CR2) 2017; 136
KW Liang (1733_CR23) 2013; 76
RF Furchgott (1733_CR4) 1991; 28
1733_CR19
ML Wu (1733_CR8) 2011; 15
X Liu (1733_CR27) 2005; 54
J Dulak (1733_CR5) 2008; 117
CC Lin (1733_CR6) 2009; 72
MM Zhang (1733_CR17) 2016; 7
NK Idriss (1733_CR3) 2008; 52
S Sayed (1733_CR24) 2015; 36
CW Yancy (1733_CR2) 2017; 136
G Wang (1733_CR9) 2010; 121
JF Ndisang (1733_CR11) 2014; 734
YH Chen (1733_CR21) 2004; 25
G Sianos (1733_CR25) 2005; 1
M Exner (1733_CR13) 2001; 8
SF Yet (1733_CR10) 2001; 89
W Bao (1733_CR20) 2010; 172
SF Yet (1733_CR26) 1999; 103
YH Chen (1733_CR12) 2002; 111
CC Lin (1733_CR29) 2008; 28
R Pechlaner (1733_CR22) 2015; 35
P Ponikowski (1733_CR1) 2016; 37
H Taha (1733_CR14) 2010; 30
P Wenzel (1733_CR28) 2015; 36
KE Daenen (1733_CR18) 2016; 32
H Qiao (1733_CR15) 2014; 179
H Kaneda (1733_CR16) 2002; 22
ML Wu (1733_CR7) 2011; 1
References_xml – volume: 136
  start-page: e137
  year: 2017
  end-page: e161
  ident: CR2
  article-title: 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America
  publication-title: Circulation
  doi: 10.1161/CIR.0000000000000509
– volume: 1
  start-page: 150
  year: 2011
  end-page: 158
  ident: CR7
  article-title: Heme oxygenase-1 in inflammation and cardiovascular disease
  publication-title: Am J Cardiovasc Dis
– volume: 35
  start-page: 229
  year: 2015
  end-page: 236
  ident: CR22
  article-title: Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with progressive atherosclerosis and incident cardiovascular disease
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/ATVBAHA.114.304729
– volume: 36
  start-page: 3437
  year: 2015
  end-page: 3446
  ident: CR28
  article-title: Heme oxygenase-1 suppresses a pro-inflammatory phenotype in monocytes and determines endothelial function and arterial hypertension in mice and humans
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehv544
– volume: 36
  start-page: 1204
  year: 2015
  end-page: 1211
  ident: CR24
  article-title: The number of GT(n) repeats in the hemeoxygenase-1 gene promoter is increased in pediatric heart failure but is unrelated to renal, antioxidant and anti-inflammatory markers
  publication-title: Pediatr Cardiol
  doi: 10.1007/s00246-015-1146-0
– volume: 72
  start-page: 109
  year: 2009
  end-page: 116
  ident: CR6
  article-title: Prognostic factors influencing the patency of hemodialysis vascular access: literature review and novel therapeutic modality by far infrared therapy
  publication-title: J Chin Med Assoc
  doi: 10.1016/S1726-4901(09)70035-8
– volume: 89
  start-page: 168
  year: 2001
  end-page: 173
  ident: CR10
  article-title: Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice
  publication-title: Circ Res
  doi: 10.1161/hh1401.093314
– volume: 1
  start-page: 219
  year: 2005
  end-page: 227
  ident: CR25
  article-title: The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease
  publication-title: EuroIntervention
– volume: 30
  start-page: 1634
  year: 2010
  end-page: 1641
  ident: CR14
  article-title: Role of heme oxygenase-1 in human endothelial cells: lesson from the promoter allelic variants
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/ATVBAHA.110.207316
– volume: 179
  start-page: 1039
  year: 2014
  end-page: 1048
  ident: CR15
  article-title: Association between heme oxygenase 1 gene promoter polymorphisms and susceptibility to coronary artery disease: a HuGE review and meta-analysis
  publication-title: Am J Epidemiol
  doi: 10.1093/aje/kwu024
– volume: 15
  start-page: 1835
  year: 2011
  end-page: 1846
  ident: CR8
  article-title: A central role of heme oxygenase-1 in cardiovascular protection
  publication-title: Antioxid Redox Signal
  doi: 10.1089/ars.2010.3726
– volume: 22
  start-page: 1680
  year: 2002
  end-page: 1685
  ident: CR16
  article-title: Heme oxygenase-1 gene promoter polymorphism is associated with coronary artery disease in Japanese patients with coronary risk factors
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/01.ATV.0000033515.96747.6F
– volume: 117
  start-page: 231
  year: 2008
  end-page: 241
  ident: CR5
  article-title: Heme oxygenase-1 and carbon monoxide in vascular pathobiology: focus on angiogenesis
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.107.698316
– ident: CR19
– volume: 121
  start-page: 1912
  year: 2010
  end-page: 1925
  ident: CR9
  article-title: Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.109.905471
– volume: 8
  start-page: 433
  year: 2001
  end-page: 440
  ident: CR13
  article-title: Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with restenosis after percutaneous transluminal angioplasty
  publication-title: J Endovasc Ther
  doi: 10.1177/152660280100800501
– volume: 7
  start-page: 83437
  year: 2016
  end-page: 83450
  ident: CR17
  article-title: Heme oxygenase-1 gene promoter polymorphisms are associated with coronary heart disease and restenosis after percutaneous coronary intervention: a meta-analysis
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.13118
– volume: 734
  start-page: 23
  year: 2014
  end-page: 34
  ident: CR11
  article-title: Heme oxygenase suppresses markers of heart failure and ameliorates cardiomyopathy in L-NAME-induced hypertension
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2014.03.026
– volume: 111
  start-page: 1
  year: 2002
  end-page: 8
  ident: CR12
  article-title: Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients
  publication-title: Hum Genet
  doi: 10.1007/s00439-002-0769-4
– volume: 54
  start-page: 778
  year: 2005
  end-page: 784
  ident: CR27
  article-title: Absence of heme oxygenase-1 exacerbates myocardial ischemia/reperfusion injury in diabetic mice
  publication-title: Diabetes
  doi: 10.2337/diabetes.54.3.778
– volume: 32
  start-page: 160
  year: 2016
  end-page: 168
  ident: CR18
  article-title: Association of HO-1 (GT)n promoter polymorphism and cardiovascular disease: a reanalysis of the literature
  publication-title: Can J Cardiol
  doi: 10.1016/j.cjca.2015.06.006
– volume: 25
  start-page: 39
  year: 2004
  end-page: 47
  ident: CR21
  article-title: Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with angiographic restenosis after coronary stenting
  publication-title: Eur Heart J
  doi: 10.1016/j.ehj.2003.10.009
– volume: 52
  start-page: 971
  year: 2008
  end-page: 978
  ident: CR3
  article-title: Hemoxygenase-1 in cardiovascular disease
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2008.06.019
– volume: 172
  start-page: 631
  year: 2010
  end-page: 636
  ident: CR20
  article-title: Association between heme oxygenase-1 gene promoter polymorphisms and type 2 diabetes mellitus: a HuGE review and meta-analysis
  publication-title: Am J Epidemiol
  doi: 10.1093/aje/kwq162
– volume: 37
  start-page: 2129
  year: 2016
  end-page: 2200
  ident: CR1
  article-title: 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehw128
– volume: 103
  start-page: R23
  year: 1999
  end-page: 29
  ident: CR26
  article-title: Hypoxia induces severe right ventricular dilatation and infarction in heme oxygenase-1 null mice
  publication-title: J Clin Invest
  doi: 10.1172/JCI6163
– volume: 76
  start-page: 312
  year: 2013
  end-page: 318
  ident: CR23
  article-title: Shorter GT repeats in the heme oxygenase-1 gene promoter are associated with a lower severity score in coronary artery disease
  publication-title: J Chin Med Assoc
  doi: 10.1016/j.jcma.2013.03.005
– volume: 28
  start-page: 739
  year: 2008
  end-page: 745
  ident: CR29
  article-title: Far infrared therapy inhibits vascular endothelial inflammation via the induction of heme oxygenase-1
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/ATVBAHA.107.160085
– volume: 28
  start-page: 52
  year: 1991
  end-page: 61
  ident: CR4
  article-title: Endothelium-dependent and -independent vasodilation involving cyclic GMP: relaxation induced by nitric oxide, carbon monoxide and light
  publication-title: Blood Vessels
– volume: 30
  start-page: 1634
  year: 2010
  ident: 1733_CR14
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/ATVBAHA.110.207316
– volume: 54
  start-page: 778
  year: 2005
  ident: 1733_CR27
  publication-title: Diabetes
  doi: 10.2337/diabetes.54.3.778
– volume: 25
  start-page: 39
  year: 2004
  ident: 1733_CR21
  publication-title: Eur Heart J
  doi: 10.1016/j.ehj.2003.10.009
– volume: 111
  start-page: 1
  year: 2002
  ident: 1733_CR12
  publication-title: Hum Genet
  doi: 10.1007/s00439-002-0769-4
– volume: 37
  start-page: 2129
  year: 2016
  ident: 1733_CR1
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehw128
– volume: 15
  start-page: 1835
  year: 2011
  ident: 1733_CR8
  publication-title: Antioxid Redox Signal
  doi: 10.1089/ars.2010.3726
– ident: 1733_CR19
  doi: 10.1186/1423-0127-17-12
– volume: 28
  start-page: 739
  year: 2008
  ident: 1733_CR29
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/ATVBAHA.107.160085
– volume: 734
  start-page: 23
  year: 2014
  ident: 1733_CR11
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2014.03.026
– volume: 72
  start-page: 109
  year: 2009
  ident: 1733_CR6
  publication-title: J Chin Med Assoc
  doi: 10.1016/S1726-4901(09)70035-8
– volume: 136
  start-page: e137
  year: 2017
  ident: 1733_CR2
  publication-title: Circulation
  doi: 10.1161/CIR.0000000000000509
– volume: 8
  start-page: 433
  year: 2001
  ident: 1733_CR13
  publication-title: J Endovasc Ther
  doi: 10.1177/152660280100800501
– volume: 32
  start-page: 160
  year: 2016
  ident: 1733_CR18
  publication-title: Can J Cardiol
  doi: 10.1016/j.cjca.2015.06.006
– volume: 36
  start-page: 1204
  year: 2015
  ident: 1733_CR24
  publication-title: Pediatr Cardiol
  doi: 10.1007/s00246-015-1146-0
– volume: 7
  start-page: 83437
  year: 2016
  ident: 1733_CR17
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.13118
– volume: 179
  start-page: 1039
  year: 2014
  ident: 1733_CR15
  publication-title: Am J Epidemiol
  doi: 10.1093/aje/kwu024
– volume: 121
  start-page: 1912
  year: 2010
  ident: 1733_CR9
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.109.905471
– volume: 36
  start-page: 3437
  year: 2015
  ident: 1733_CR28
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehv544
– volume: 52
  start-page: 971
  year: 2008
  ident: 1733_CR3
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2008.06.019
– volume: 22
  start-page: 1680
  year: 2002
  ident: 1733_CR16
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/01.ATV.0000033515.96747.6F
– volume: 103
  start-page: R23
  year: 1999
  ident: 1733_CR26
  publication-title: J Clin Invest
  doi: 10.1172/JCI6163
– volume: 1
  start-page: 150
  year: 2011
  ident: 1733_CR7
  publication-title: Am J Cardiovasc Dis
– volume: 76
  start-page: 312
  year: 2013
  ident: 1733_CR23
  publication-title: J Chin Med Assoc
  doi: 10.1016/j.jcma.2013.03.005
– volume: 172
  start-page: 631
  year: 2010
  ident: 1733_CR20
  publication-title: Am J Epidemiol
  doi: 10.1093/aje/kwq162
– volume: 35
  start-page: 229
  year: 2015
  ident: 1733_CR22
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/ATVBAHA.114.304729
– volume: 1
  start-page: 219
  year: 2005
  ident: 1733_CR25
  publication-title: EuroIntervention
– volume: 28
  start-page: 52
  year: 1991
  ident: 1733_CR4
  publication-title: Blood Vessels
– volume: 117
  start-page: 231
  year: 2008
  ident: 1733_CR5
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.107.698316
– volume: 89
  start-page: 168
  year: 2001
  ident: 1733_CR10
  publication-title: Circ Res
  doi: 10.1161/hh1401.093314
SSID ssj0015919
Score 2.2485151
Snippet Heme oxygenase (HO)-1 is a rate-limiting enzyme for degrading heme into carbon monoxide. Longer (GT) n repeat of the HO-1 gene (HMOX1) promoter has a lower...
Heme oxygenase (HO)-1 is a rate-limiting enzyme for degrading heme into carbon monoxide. Longer (GT) repeat of the HO-1 gene (HMOX1) promoter has a lower...
Heme oxygenase (HO)-1 is a rate-limiting enzyme for degrading heme into carbon monoxide. Longer (GT)n repeat of the HO-1 gene (HMOX1) promoter has a lower...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 615
SubjectTerms Alleles
Biomedical Engineering and Bioengineering
Carbon monoxide
Cardiac Surgery
Cardiology
Cardiovascular disease
Catheterization
Coronary artery
Coronary artery disease
Coronary vessels
Ejection fraction
Genotypes
Heart diseases
Heme
Heme oxygenase (decyclizing)
Medicine
Medicine & Public Health
Multivariate analysis
Original Article
Oxygenase
Polymerase chain reaction
Subgroups
Transcription
Vascular Surgery
Title Subjects with coronary artery disease and reduced ejection fraction have longer (GT)n repeats in the heme-oxygenase 1 gene promoter
URI https://link.springer.com/article/10.1007/s00380-020-01733-7
https://www.ncbi.nlm.nih.gov/pubmed/33388910
https://www.proquest.com/docview/2510298250
https://www.proquest.com/docview/2475093804
Volume 36
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9RAEB9qC-KLaOtHtJYRRBRduGQ3yebxKr2Win3qQX0K-xWqtHtHrhXv2X_c2c2HSFvBl00gm8mS-e1kZue3E4A3pGJNARtnylWCCSsLVqm8YlqkpnCVJUxFlu9JcTQXx2f5Wb8pbDWw3YeUZLTU42a3kMSasBDuEIo4Z-U92Mopdg9Ernk2HXMHeZV2FfbIwhBey36rzO0y_v4c3fAxb-RH42dn9gge9v4iTjsFP4YN57dhZ-opVr5c41uMDM64NL4N97_0ifId-EUGIaywrDAstKIJdQpUu8bI4Fxjn5ZB5S22oXirs-i-R1aWx6btNjvgufrh8GIRhoXvDk_fe-q7JNu9wm8eyXHEc3fp2OLnmkAYpKVIJw6XkeHn2icwnx2cfjpi_f8WmOGpIFtDqjLaiDzVthBKW8MzqSdpo3hhubJukjU8U9w21GRNyXMnC0Fv2xgpG634U9j0C--eAyrFK1VKkVmVUuO0IBkEilzlmTTSJJAOr702fTHy8E-Mi3osoxxVVZOq6qiqukzgw3jPsivF8c_eu4M2635armpy5kLJeXL7Eng9XqYJFbIkyrvFNfURwYkiaSKBZx0KxsdxCugl4SqBjwMs_gi_eywv_q_7S3iQBeZMpFXuwuZVe-1eketzpfdgazrb3z8Jx8Ovnw_2IvJ_Axrx_FY
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3daxQxEB-0gvZFtPVjteoIIooN3G6yu9nHQ6yntn26g74t-VqqtLljry3es_-4k-yHSFXwJSzs7GzI_DKZyUwmAK9IxJocNs6UqwQTVhasUnnFtEhN4SpLmIpZvsfFbCE-n-Qn_aGw9ZDtPoQko6YeD7uFINaEBXeHUMQ5K2_CLTIGZMDyIpuOsYO8SrsKe6RhCK9lf1Tmzzx-X46u2ZjX4qNx2Tm4B3d7exGnnYDvww3nd2B36slXPt_ga4wZnHFrfAduH_WB8l34QQoh7LCsMWy0ogl1ClS7wZjBucE-LIPKW2xD8VZn0X2LWVkem7Y77ICn6srh2TJ0C998nL_1RLsi3b3Grx7JcMRTd-7Y8vuGQBi4pUgPDlcxw8-1D2Bx8GH-fsb6-xaY4akgXUOiMtqIPNW2EEpbwzOpJ2mjeGG5sm6SNTxT3DbUZE3JcycLQaNtjJSNVvwhbPmld48BleKVKqXIrEqpcVoQDwJFrvJMGmkSSIdhr01fjDzciXFWj2WUo6hqElUdRVWXCbwbv1l1pTj-Sb03SLPup-W6JmMulJwnsy-Bl-NrmlAhSqK8W14SjQhGFHETCTzqUDD-jpNDLwlXCewPsPjF_O99efJ_5C_gzmx-dFgffjr-8hS2s5BFE1Ms92Dror10z8gMutDPI-p_AliA_Dk
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB5BkSouiLY8Ai0MEkIgsLqJncQ5rgpLeVUculJvkV9RQa13ld0i9swf79jJBlABiYsVKZOJ5flsz3geBnhKItZksHGmXCWYsLJglcorpkVqCldZwlSM8j0qDqfi_Ul-8ksWf4x2X7sku5yGUKXJL_fnttkfEt-CQ2vEgulDiOKcldfhhgjZwIToaTYe_Ah5lXbV9mi1IeyWfdrMn3n8vjVd0Tev-ErjFjS5Dbd63RHHnbC34Jrz27Az9mQ3n6_wGcZoznhMvg2bn3qn-Q78oMUhnLYsMBy6ogk1C1S7whjNucLeRYPKW2xDIVdn0X2NEVoem7ZLfMBT9c3h2Sx0C5-_PX7hiXZO6_gCv3gkJRJP3bljs-8rAmTgliI9OJzHaD_X3oHp5M3xwSHr715ghqeC1h0Sm9FG5Km2hVDaGp5JPUobxQvLlXWjrOGZ4rahJmtKnjtZCBptY6RstOJ3YcPPvLsPqBSvVClFZlVKjdOCeBBAcpVn0kiTQLoe9tr0hcnD_Rhn9VBSOYqqJlHVUVR1mcDL4Zt5V5bjn9S7a2nW_RRd1KTYhfLzpAIm8GR4TZMreEyUd7MLohFBoSJuIoF7HQqG33Ey7iXhKoFXa1j8ZP73vjz4P_LHsPn59aT--O7ow0O4mYWAmhhtuQsby_bC7ZFGtNSPIugvAbaYAHs
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Subjects+with+coronary+artery+disease+and+reduced+ejection+fraction+have+longer+%28GT%29n+repeats+in+the+heme-oxygenase+1+gene+promoter&rft.jtitle=Heart+and+vessels&rft.au=Liang+Kae-Woei&rft.au=Wen-Jane%2C+Lee&rft.au=Wen-Lieng%2C+Lee&rft.au=Wu+Jen-Pey&rft.date=2021-05-01&rft.pub=Springer+Nature+B.V&rft.issn=0910-8327&rft.eissn=1615-2573&rft.volume=36&rft.issue=5&rft.spage=615&rft.epage=620&rft_id=info:doi/10.1007%2Fs00380-020-01733-7&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0910-8327&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0910-8327&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0910-8327&client=summon